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ABSTRACT
The effect of the transplant dose of each cell subset on engraftment kinetics and transplantation outcomes was
evaluated in HLA-identical allogeneic peripheral blood stem cell transplantation (PBSCT). Sixty-nine patients
were included in this retrospective study. Engraftment kinetics, transplantation outcomes, and immune
reconstitution up to 1 year after transplantation were analyzed according to the transplant dose of CD34 and
non-CD34 cells, including natural killer (NK) cells and CD8 cytotoxic T (Tc) cells. An accelerated
neutrophil engraftment was strongly associated with a higher transplant dose of NK cells (12 versus 16 days,
P < .001) and Tc cells (13 versus 16 days, P < .001) but not CD34 cells (P  .442). Survival analyses revealed
a favorable prognosis for patients who received a higher dose of non-CD34 cell subsets, rather than CD34
cells, in terms of overall survival (OS; P  .024 for NK cells and .050 for Tc cells) and nonrelapse mortality
(NRM; P  .005 for NK cells, .060 for Tc cells). In addition, a higher transplant dose of NK and Tc cells was
correlated with a faster lymphoid reconstitution. In multivariate analyses, rapid neutrophil engraftment was
correlated with a higher transplant dose of NK cells (P  .001) and Tc cells (P  .004). Moreover, an increased
OS was associated with the NK cell dose (P  .007) and chronic graft-versus-host disease (P  .009), whereas
a decreased NRM was associated with the NK dose (P  .024). In conclusion, in a PBSCT setting, a higher
transplant dose of NK and Tc cells accelerated neutrophil engraftment, improved the immune reconstitution,
and decreased NRM, thereby increasing OS after allogeneic PBSCT.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Allogeneic peripheral blood stem cell transplanta-
ion (PBSCT) can decrease the chance of infection by
hortening the neutropenic period after transplanta-
ion. However, the exact mechanism of engraftment rinetics is not fully understood. CD34 stem cells
ave been proposed as the most important component
f a transplant graft that inﬂuences engraftment ki-
etics [1,2]. After transplantation, 2 phases of donor
ell engraftment can be observed: an early period of
econstitution that occurs immediately after stem cell
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D. H. Kim et al.720ransplantation (SCT) and then a slower, more stable
ong-term chimerism [3]. In addition to CD34 stem
ells, cotransplanted non-CD34 graft composites,
uch as CD3 T cells, have been regarded as an
mportant determinant for preventing graft rejection,
specially in the case of CD34 cell selected SCT [4]
r cord blood transplantation [5]. Further, patients
ho receive a higher dose of CD34 cells also have a
ropensity to receive a higher dose of non-CD34 cell
omponents, including CD4 helper T (Th), CD8
ytotoxic T (Tc), CD19 B, and CD56 natural killer
NK) cells.
Recently, the transplant dose of Tc cells, a subset
f CD3 T cells, has been signiﬁcantly correlated
ith transplantation outcomes in a reduced intensity
CT setting [6], where patients who received a higher
ose of CD8 Tc cells showed a faster full donor-type
-cell chimerism and increased event-free and
verall survival (OS). In addition, we previously
eported that a higher transplant dose of CD56
K cells accelerates engraftment, decreases nonre-
apse mortality (NRM), and improves the immune
econstitution of NK and Tc cells [7].
Accordingly, the presented study evaluated the
ffect of the transplant dose of each cell subset on
ngraftment kinetics and transplantation outcomes for
conﬁned group of patients who had undergone al-
ogeneic PBSCT from HLA-matched donors. The
rimary objective was to evaluate neutrophil and
latelet engraftments relative to transplant doses
f non-CD34 cells, including mononuclear cells
MNCs), lymphonuclear cells (LNCs), CD3 T cells,
D4 Th cells, CD8 Tc cells, CD19 B cells, and
D56 NK cells. The secondary objective was to
valuate the effect of these cell doses on transplanta-
ion outcomes, including OS, cumulative incidence of
raft-versus-host disease (GVHD), relapse, NRM,
nd immune reconstitution up to 1 year after trans-
lantation.
ETHODS
atient Characteristics and Transplantation
rocedures
Sixty-nine patients who received allogeneic PB-
CT from HLA-matched sibling donors at Kyung-
ook National University Hospital between Decem-
er 1996 and November 2004 were enrolled in the
resent study. Patients’ characteristics included a me-
ian age of 36 years (range, 1758) and a male-to-
emale ratio of 59:41 (n  41:28). Patients’ diseases
nd disease states are presented in Table 1.
Transplantation procedures were conducted as
reviously described [8,9]. Brieﬂy, the conditioning
egimens for the allogeneic recipients were busulfan/
ytoxan (n  51) myeloablative or ﬂudarabine-based meduced intensity conditioning (RIC; n  18). All
atients received peripheral blood stem cells (PBSCs).
ransplant doses of CD34 and non-CD34 cells are
isted in Table 1. From day 1, granulocyte colony-
timulation factor (G-CSF; 300 g subcutaneously)
as given to patients. Acute GVHD prophylaxis
onsisted of cyclosporine (3 mg · kg1 · d1 intra-
enously, 24-hour continuous infusion, Cipol-N,
hongKunDang, Seoul, Korea) beginning on day 1
nd methotrexate on days 1 (15 mg/m2), 3 (10
g/m2), 6 (10 mg/m2), and 11 (10 mg/m2) in 64
atients, and 5 patients received cyclosporine A alone
n  3) or FK506/methotrexate (n  2). Infection
rophylaxis consisted of ciproﬂoxacin (250 mg twice
aily orally), metronidazole (500 mg thrice daily
rally), and ﬂuconazole (100 mg/d orally), beginning
ith the initiation of conditioning, and acyclovir (600
g twice daily orally) from day 1 to day 180.
otrimoxazole was started after engraftment.
BSC Collection and Immunophenotypic Analysis
f Allografts and Peripheral Blood Cells
PBSCs were harvested from the donors on day 5
fter mobilization treatment with G-CSF alone (10
g/kg for 5 consecutive days, n  16), granulocyte-
able 1. Patient Characteristics and Transplantation Procedures
n  69)*
emale/Male, % 28/41 (41:59)
ge, median (range) 36 (1758)
iagnosis, n (%)
AML/ALL 41/9 (59/13)
CML/MDS 8/2 (12/3)
Lymphoma 9 (13)
Advanced disease 36 (52)
onditioning, n (%)
BuCy 51 (74)
Fludarabine-based RIST 18 (26)
VHD prophylaxis, n (%)
CSA/MTX 64 (93)
CSA alone 3 (4)
FK506/MTX 2 (3)
ransplant cell dose, mean 
SE (median, range)†
MNCs 9.07  0.49 (8.22, 1.6924.15)
Lymphoid cells 4.44  0.37 (3.78, 0.4921.01)
CD34 cells 8.63  0.57 (7.20, 2.2220.60)
CD3 T cells 2.79  0.19 (2.46, 0.339.87)
CD19 B cells 1.00  0.12 (0.85, 0.055.88)
CD4 Th cells 1.70  0.14 (1.45, 0.116.51)
CD8 Tc cells 1.14  0.09 (0.91, 0.223.57)
CD56 NK cells 0.63  0.09 (0.48, 0.085.25)
AML/ALL indicates acute myeloblastic leukemia/acute lympho-
blastic leukemia; CML/MDS, chronic myeloblastic leukemia/
myelodysplastic syndrome; BuCy, busulfan-Cytoxan; RIST, re-
duced-intensity stem cell transplantation; CSA/MTX, cyclosporine
A/methotrexate.
Cell doses are presented as108/kg except for CD34 cell counts,
which are presented as 106/kg.acrophage colony-stimulating factor (GM-CSF) alone
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Effect of Transplant Dose of Non-CD34 Cells on Engraftment Kinetics 72110 g/kg for 5 consecutive days, n  10), and G-CSF/
M-CSF (5 g/kg of G-CSF plus 5 g/kg of GM-CSF
or 5 consecutive days, n  43), as reported previously
10,11]. The PBSC collection criteria included a mini-
um target dose of CD34 cells, ie, 3  106/kg.
Quantitative measurements of lymphocyte subsets
n PBSCs and peripheral blood were conducted ac-
ording to hospital protocol according to a ﬂow cyto-
etric method, as previously described [7]. In brief,
-color (ﬂuorescein isothiocyanate and phycoerythrin)
ow cytometric immunophenotyping was performed.
D3 T cells, CD3/4 Th cells, CD3/8 Tc cells,
D19 B cells, and CD3/56NK cells were ana-
yzed on an FACScan (Becton Dickinson, Mountain
iew, Calif). Appropriate amounts and combinations
f undiluted monoclonal antibodies directly conju-
ated to ﬂuorochromes (DN Immune Panel kit, Di-
onA Inc., Seoul, Korea) were added to 100 L of
ells isolated from blood anticoagulated with ethyl-
nediaminetetraacetic acid using a lysis buffer, fol-
owed by incubation for 15 minutes at room temper-
ture. Lymphocytes were then gated based on their
og side scatter and forward scatter characteristics.
he absolute count for each cellular subset was cal-
ulated as the product of the absolute white blood cell
ount, lymphocyte differential percentage, and cellu-
ar subset percentage, as evaluated by ﬂow cytometry.
erial measurements of peripheral lymphoid cells
ere also performed with ﬂow cytometry at 3, 6, and
2 months after allogeneic SCT.
efinitions
The day of stem cell infusion was deﬁned as day 0.
cute and chronic GVHDs were diagnosed and
raded according to established criteria [12,13]. OS
as deﬁned as time from transplantation until death
rom any cause. NRM was deﬁned as a death not
elated to recurrence or disease progression. The cu-
ulative incidence of relapse was deﬁned as time from
ransplantation until disease progression. Advanced
iseases were deﬁned as any disease relapse after pre-
ious allogeneic or autologous SCT, acute leukemia
fter the ﬁrst complete remission, Ph acute lympho-
lastic leukemia, advanced-phase chronic myeloblastic
eukemia, or primary refractory or multiple relapse
iseases.
tatistical Analysis
Results were analyzed according to information
vailable on July 2005. Various clinical and laboratory
ata on patients were retrieved from the allogeneic
CT database and medical records. Informed consent
as given by recipients and donors for the present
tudy. The Kaplan-Meier method was used to obtain
ctuarial estimates of patient events, and differences in
edians for each graft composite were assessed with cog-rank test with respect to engraftment kinetics, OS,
RM, and risk of relapse. In addition, differences in
edians and proportions of outcomes after transplan-
ation, such as GVHD and survival, were determined
ith the Mann-Whitney U test and chi-square test,
espectively.
Cumulative incidences of neutrophil/platelet en-
raftment, NRM, relapse, and OS were calculated
ith the Kaplan-Meier method. Differences in OS,
RM, probability of relapse, and opportunistic infec-
ions according to transplant doses of CD34, NK,
nd Tc cells were compared with log-rank test.
For multivariate survival analyses to identify fac-
ors inﬂuencing neutrophil/platelet engraftment, lin-
ar regression and multivariate survival analyses using
he Cox proportional hazard model were adopted. In
inear regression analysis, engraftment day and each
ransplant cell dose were incorporated into the model.
eanwhile, in the Cox proportional hazard model, each
ransplant cell dose was dichotomized by the median
alue and incorporated into the model. The following
ariables were included in the ﬁnal model: transplant
oses of MNCs, LNCs, CD34 cells, CD3 T cells,
D4 Th cells, CD8 Tc cells, CD19 B cells, and
D56 NK cells as continuous variables for linear
egression analysis and categorical variables for the
ox multivariate analysis.
In addition, the Cox proportional hazard model
as used to identify prognostic factors for OS, NRM,
nd relapse, and the following variables were included
n the ﬁnal model: disease risk (standard versus ad-
anced disease), acute GVHD (grades 0-2 versus
rades 3 and 4), chronic GVHD (no versus yes), and
ransplant dose of CD34, CD4 Th, CD8 Tc, and
D56 NK cells by using the median as the cutoff
alue. In all multivariate analyses, backward condi-
ional procedures were conducted until the P value for
he likelihood ratio test was .05. Hazard ratio (HR)
nd 95% conﬁdence interval (95% CI) were also es-
imated.
Recovery kinetics for each lymphocyte subset were
nalyzed according to the transplant cell dose by using
general linear model based on serial data from pa-
ients taken 3, 6, and 12 months after SCT and are
resented in ﬁgures as means and 50% of SEs based
n a smothering method using the spline function
echnique. A cutoff P value equal to .05 was adopted
or all statistical analyses, except for repeated measure-
ents for the general linear model, where .1 was
dopted as the cutoff P value. Statistical data were
btained with SPSS 11.5 (SPSS, Chicago, Ill).
ESULTS
orrelation of PBSC Subsets
Transplant cell doses of MNCs, LNCs, CD34ells, CD3 T cells, CD4 Th cells, CD8 Tc cells,
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D. H. Kim et al.722D19 B cells, and CD56 NK cells are listed in
able 1. No difference was noted in the percentage of
ach lymphocyte subset in PBSCs according to the
ytokine mobilization regimen (data not shown).
owever, strong correlations were noted across doses
f different cell subsets, not only between Tc and NK
ells (r  .668, P  .01) but also among various
ymphocyte subsets. However, no correlation was
ound between CD34 and Tc cells (r  .098) or
etween CD34 and NK cells (r  .072).
ngraftment Kinetics According to Transplant
ose of CD34 and Non-CD34 Cells
Neutrophil engraftment was achieved in 65 of 69
atients (94%), with a median of 14 days (95% CI, 12.8
o 15.2; range, 9 to 30), whereas platelet engraftment was
chieved in 63 of 69 patients (91%), with a median of 14
ays (95% CI, 12.4 to 15.6; range, 9 to 161).
When comparing engraftment kinetics according
o transplant dose of CD34 and non-CD34 cells,
ngraftment of neutrophils was inversely correlated
ith that of NK (P  .001), Tc (P  .001), MNC
P  .005), Th (P  .015), and B (P  .032) cells, but
ot with that of CD34 cells (P  .442), as presented
n Table 2. There was no signiﬁcant correlation be-
ween platelet engraftment kinetics and these cell
omponents. Cumulative incidence of neutrophil en-
raftment according to transplant dose of CD34 and
on-CD34 cells showed a similar trend (Figure 1A-C).
ransplantation Outcomes According to
ransplant Dose of CD34 and Non-CD34 Cells
Transplantation outcomes were as follows: the
-year OS rate was 48.3	 6.1%, cumulative incidence
f NRM was 34.5 	 6.3%, relapse was 43.6 	 6.7%,
verall incidence of grade 2-4 acute GVHD was 68.1 	
.1%, overall incidence of grade 3/4 severe acute
VHD was 23.3 	 6.1%, 1-year incidence of overall
hronic GVHD was 78.7 	 5.9%, and overall inci-
ence of extensive chronic GVHD was 40.9 	 7.1%.
ith a median follow-up duration of 409 days (range,
to 2360; 998 days for survivors, with a range of 202
o 2,360 days), 38 patients died from progression of
rimary disease (n  15) or NRM (n  23), including
nfection (n  15), GVHD (n  2), infection and
VHD (n  3), or other causes (n  2).
When comparing transplantation outcomes ac-
ording to the 50th percentile of each graft composite
Table 2), OS was signiﬁcantly favorable to a higher
ransplant dose of NK (P  .024), Th (P  .045) and
c (P  .050) cells, whereas NRM was only signiﬁ-
antly in favor of a higher dose of NK cells (P .005).
owever, no difference was noted in the probability
f relapse for each graft composite.
With regard to transplant dose of CD34 cells
nd other non-CD34 cell subsets, such as NK or Tc sells, the contribution of the non-CD34 cell dose to
RM was more substantial than the contribution of
he CD34 cell dose (Table 3). In summary, the
D34 transplant cell dose was not associated with
S (Figure 2A,B) but was associated with develop-
ent of chronic GVHD (P  .032; Table 3). Con-
ersely, the transplant dose of NK and Tc cells was
igniﬁcantly associated with OS and NRM (Figure
C-F) but not with acute or chronic GVHD (Table 3).
ontribution of Transplant Dose of Tc and NK
ells on Myeloablative and RIC Settings
To deﬁne the effect of transplant dose of Tc and
K cells on each setting of myeloablative and RIC, we
erformed separate analyses by grouping patients ac-
ording to myeloablative versus RIC treatment. Inter-
stingly, we found that the Tc and NK cell dose
igniﬁcantly inﬂuenced OS (P .030 for Tc cells, P
023 for NK cells) and NRM (P  .045 for Tc cells,
 .028 for NK cells) in the myeloablative group
n  51) but not in the RIC group (n  18).
ontribution of Engraftment Kinetics
o Transplantation Outcomes
The role of neutrophil and platelet engraftment
inetics was analyzed in relation to transplantation
utcomes. In analyses using a univariate Cox regres-
ion with engraftment day as the continuous variable,
eutrophil engraftment kinetics were strongly associ-
ted with OS (P  .009; HR, 1.090; 95% CI,
.0221.162) and NRM (P  .004; HR, 1.120; 95%
I, 1.037 to 1.209) but not with relapse risk; however,
o association was observed with platelet engraftment
inetics. When dichotomizing patients based on me-
ian day of engraftment (ie, 14 versus 14 days
or neutrophils or platelets), patients with a rapid
eutrophil engraftment showed a better OS (71.4 	
.5% versus 36.7 	 8.0%, P  .008) and lower
RM (11.6 	 6.3% versus 44.9 	 9.3%, P  .008),
hereas those with a rapid platelet engraftment did
ot.
mmune Reconstitution Dependent on Transplant
ose of CD56 NK and CD8 Tc Cells, Rather
han CD34 Cell Dose
To investigate the inﬂuence of transplant dose of
D34 and non-CD34 cells on serial reconstitution
f each lymphocyte subset from 3 months to 1 year
fter SCT, a general linear model was applied to the
erial data for each subset (Figure 3). As shown in
igure 3, the recovery trend beneﬁted from a higher
ransplant dose of NK and Tc cells but not of CD34
ells. In addition, a higher transplant dose of NK cells
as strongly associated with subsequently faster
D3 T-cell (P  .092) and CD56 NK cell recon-
titutions between 3 months and 1 year after trans-
Table 2. Transplantation Outcomes and Engraftment Kinetics According to Transplant Dose of CD34 and Non-CD34 Cells (by log-rank test)*
Engraftment Kinetics, Median (95% CI) Transplantation Outcomes, Mean  SE
WBC (d) ANC (d) PC (d) OS at 2 y, % NRM at 2 y, % Relapse at 2 y, %
MNC
>50th percentile 12.0 (10.913.1) .018 13.0 (12.014.0) .005 12.0 (10.713.3) .058 50.9  8.6 .580 24.7  7.7 .160 35.1  9.2 .255
<50th percentile 15.0 (13.616.4) 16.0 (14.417.6) 17.0 (13.720.3) 45.6  8.7 43.8  9.4 52.1  9.5
LNC
>50th percentile 12.0 (10.913.1) .052 13.0 (11.914.1) .057 13.0 (11.114.9) .930 57.0  8.7 .243 19.0  7.0 .088 38.6  9.3 .520
<50th percentile 15.0 (13.017.0) 16.0 (15.017.0) 15.0 (11.918.1) 41.6  9.2 46.9  10.2 50.1  10.5
CD34
>50th percentile 13.0 (11.914.1) .689 15.0 (12.717.3) .442 15.0 (13.616.4) .642 55.8  8.6 .171 26.6  8.3 .111 45.6  9.2 .735
<50th percentile 14.0 (12.615.4) 14.0 (12.615.4) 13.0 (11.814.2) 40.7  8.5 42.1  9.1 41.3  9.9
CD3
>50th percentile 13.0 (12.014.0) .008 13.0 (12.213.8) .010 14.0 (12.415.6) .705 56.5  8.5 .217 20.7  7.0 .078 37.7  9.2 .461
<50th percentile 15.0 (13.916.1) 16.0 (14.917.1) 16.0 (13.318.7) 41.2  8.7 46.6  9.7 49.8  9.7
CD19
>50th percentile 12.0 (10.813.2) .085 13.0 (12.113.9) .032 13.0 (11.714.3) .298 54.2  9.1 .506 20.0  7.3 .192 35.3  9.6 .188
<50th percentile 15.0 (13.416.6) 16.0 (14.817.2) 16.0 (13.518.5) 42.4  9.8 47.8  10.8 60.1  11.2
CD4
>50th percentile 12.0 (10.313.8) .013 13.0 (12.113.9) .015 13.0 (11.514.5) .964 64.7  9.1 .045 17.6  7.2 .123 36.8  9.9 .223
<50th percentile 15.0 (12.517.5) 16.0 (14.717.3) 16.0 (13.518.5) 34.2  9.1 49.1  11.2 54.6  11.1
CD8
>50th percentile 12.0 (10.813.2) <.001 13.0 (11.914.0) <.001 13.0 (11.914.1) .086 61.4  9.2 .050 17.5  7.1 .060 33.8  9.8 .129
<50th percentile 15.0 (13.516.5) 16.0 (15.116.8) 16.0 (13.418.6) 37.1  9.4 55.8  11.7 57.1  11.1
CD56
>50th percentile 12.0 (11.013.0) <.001 12.0 (10.913.1) <.001 13.0 (11.714.3) .246 64.9  9.0 .024 10.6  5.8 .005 38.8  9.7 .298
<50th percentile 15.0 (13.716.3) 16.0 (14.817.1) 16.0 (13.918.0) 32.1  9.0 56.8  10.6 55.3  11.4
*WBC indicates white blood cell count; ANC, absolute neurtrophil count; PC, platelet count.
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D. H. Kim et al.724lantation (P  .090) and marginally correlated with
he CD4 Th-cell and CD8 Tc cell recovery be-
ween 3 months and 1 year. Further, a higher trans-
lant dose of Tc cells was strongly associated with a
ubsequently faster CD4 Th-cell recovery between 3
onths and 1 year (P  .062).
ultivariate Analysis of Engraftment Kinetics
nd Transplantation Outcomes
To ascertain which cellular composite affected
eutrophil and platelet engraftment kinetics, linear
igure 1. Differences in engraftment kinetics for neutrophils accor
D8 Tc cells. (A) There is no difference in neutrophil engraftment
s faster neutrophil engraftment in patients who received a higher
able 3. Transplantation Outcomes, Including Engraftment Kinetics, O
ransplant Dose of CD34 Cells
CD34 Cells
<50th
Percentile
(n  34)
>50th
Percentile
(n  35) P
P
cute GVHD, n (%)
Overall 25 (78) 27 (79) .898
Grade 2-4 20 (63) 23 (68) .661
Grade 3-4 3 (9) 9 (27) .072
hronic GVHD, n (%) n  27 n  31
Overall 17 (63) 27 (87) .032
Extensive 10 (37) 15 (48) .384
vents, n (%)
Relapse 13 (38) 14 (40) .881
Deaths 20 (59) 17 (49) .393
NRMs 14 (41) 9 (36) .173 12 (43egression and multivariate analyses using the Cox
roportional hazard model were performed. In linear
egression analysis, the Tc cell dose was strongly as-
ociated with neutrophil engraftment kinetics in an
nverse manner (P  .003, standardized coefﬁcient 
.397); in the Cox proportional hazard model, a rapid
eutrophil engraftment was correlated with a higher
ransplant dose of NK cells (P  .001; probability of
ngraftment, 4.926) and Tc cells (P  .004; probabil-
ty of engraftment, 3.401; Table 4).
In terms of OS and NRM (Table 4), increased OS
transplant dose of (A) CD34 cells, (B) CD56 NK cells, and (C)
s according to transplant CD34 cell dose; (B, C) in contrast, there
nt dose of NK or Tc cells.
ce of GVHD, Relapse, Death, or Opportunistic Infections, According to
CD8 Tc Cells CD56 NK Cells
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Percentile
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Percentile
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Percentile
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f NK cells (P  .007; HR, .262) and occurrence of
hronic GVHD (P  .009; HR, .267), whereas a
ecreased NRM was strongly associated with a higher
ransplant dose of NK cells (P  .024; HR, .091).
ISCUSSION
The present study investigated the effect of the
ransplant dose of CD34 and non-CD34 cells, es-
ecially NK and Tc cells, on neutrophil engraftment
inetics and transplantation outcomes after HLA-
dentical sibling PBSCT. First, a higher transplant
ose of NK and Tc cells, rather than of CD34 cells,
as signiﬁcantly correlated with rapid neutrophil en-
raftment. Second, a higher transplant dose of NK
igure 2. OS and NRM according to transplant dose of (A, B) CD3
s a small but nonsigniﬁcant trend toward improved survival outcom
C-F) Improved survival outcomes were apparent for some time amnd Tc cells was strongly associated with better OS tnd NRM, whereas the transplant dose of CD34
ells was not. Third, long-term immune reconstitu-
ion within 1 year after transplantation was affected by
he transplant dose of NK and Tc cells, meaning that
he transplant dose of non-CD34 cell composites
eeds to be considered in addition to the C34 cell
ose in a PBSCT setting.
For successful transplantation, a sufﬁcient number
f CD34 cells needs to be transplanted. A higher
ose of CD34 cells has been reported to lower the
ncidence of relapse by increasing chronic GVHD,
hereby decreasing the risk of relapse by the graft-
ersus-leukemia effect [14-16]. However, some debate
emains as to whether a higher transplant dose of
D34 cells is associated with improved transplant
utcomes. Mohty et al [2] reported that a higher
s, (C, D) CD56 NK cells, and (E, F) CD8 Tc cells. (A, B) There
ng patients who received a higher transplant dose of CD34 cells.
atients who received a higher transplant dose of NK or Tc cells.4 cell
e amoransplant dose of CD34 cells increased NRM,
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D. H. Kim et al.726ostly from GVHD-associated mortality. However,
n addition to CD34 cells, a substantial number of
on-CD34 cells are cotransplanted with CD34
ells, especially CD3T cells. The contribution of
igure 3. Immune reconstitution of CD8Tc cells/NK cells with C
c, and CD56 NK cells. The mean value is marked on each p
ubsequently faster CD3 T cell (P  .092) and CD56 NK cell rec
n addition, a higher transplant dose of Tc was strongly associated
year (P  .062).D3 T cells to the prevention of graft rejection has ueen based on the following observations: (1) rejection
ssociated with T-cell–depleted marrow can be over-
ome by adding a small quantity of donor CD8 cells
r thymocytes to the grafts [4], and (2) in a double
and CD4Th cells according to transplant dose of CD34, CD8
higher transplant dose of NK cells was strongly associated with
tion between 3 months and 1 year after transplantation (P  .090).
subsequently faster CD4 Th cell recovery between 3 months andD3T
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Effect of Transplant Dose of Non-CD34 Cells on Engraftment Kinetics 727redominantly determined by the unit containing the
igher CD3 T-cell count [5]. Thus, 2 mechanisms
ave been proposed for donor T-cell function in en-
raftment after allogeneic SCT: (1) donor T cells may
rovide the lymphokines necessary for donor stem cell
ifferentiation and proliferation in the marrow niche
nd (2) donor T cells may eliminate any residual host
ells in the marrow, thereby preventing grafted stem
ells from being rejected [3]. As a consequence, al-
hough the mechanism of engraftment after allogeneic
CT has not been fully investigated, the contribution
f non-CD34 cells to engraftment kinetics appear to
e relevant.
In cytokine-mobilized PBSCs, various kinds of non-
D34 cells are cotransplanted with CD34 stem cells,
uch as CD8 Tc or CD56 NK cells [17]. Recently,
ao et al [6] reported that a higher transplant dose of
D8 T cells favorably correlated with a full donor
lood T-cell chimerism and transplantation outcomes,
mplying that non-CD34 cells can affect engraftment
inetics and transplantation outcomes as well as CD34
ells. In a previous study, we also observed that patients
ho received a higher dose of NK cells showed faster
eutrophil engraftment, increased OS, and faster im-
une reconstitution within 1 year after transplantation
7]. Therefore, to extend this previous study, the contri-
ution of non-CD34 cells, such as MNCs, LNCs,
D3 T cells, CD4 Th cells, CD8 Tc cells, CD19
cells, and CD56 NK cells to engraftment kinetics
fter allogeneic PBSCT was retrospectively analyzed,
nd the transplant dose of NK and Tc cells was found to
e strongly correlated with neutrophil engraftment and
RM.
In the present study, neutrophil engraftment was
trongly correlated with the transplant dose of NK
nd Tc cells, but not with the dose of CD34 cells [4].
able 4. Multivariate Analysis of Engraftment Kinetics for
eutrophils, OS, and NRM
eutrophil engraftment
Transplant NK dose,
>50th percentile
.001† 4.926 (1.953–12.346)‡
Transplant Tc dose,
>50th percentile
.004† 3.401 (1.462–7.874)‡
Transplant Tc dose as
continuous variable*
.003† 0.397 (standardized
coefficients)
S
Transplant NK dose,
>50th percentile
.007† 0.262 (.099–.692)§
Chronic GVHD .009† 0.267 (.098–.723)§
RM
Transplant NK dose,
>50th percentile
.024† 0.091 (.011–.726)§
Performed by linear regression analysis.
P value.
Probability of engraftment (95% CI).
HR (95% CI).owever, Cao et al [6] reported no correlation be- Gween the dose of CD34, CD3, CD4, and CD8
ells and neutrophil and platelet engraftment. The
ole of NK cells in neutrophil engraftment can be
xplained as follows: (1) graft failure is inversely cor-
elated with the donor chimerism level of NK cells on
ays 10 to 30 [18] and (2) NK cell activities immedi-
tely after allogeneic SCT include repopulating do-
or-type lymphocytes that mediate cytotoxicity to the
ost cells in the marrow niche [19-22]. The role of Tc
ells in neutrophil engraftment has been proposed to
nclude supporting the initial presence of donor pro-
enitor cells in a perforin- and/or FasL-mediated
anner and maintaining long-term engraftment after
n allogeneic MHC class I/II mismatched bone mar-
ow transplantation [3]. Therefore, addition of NK
nd Tc cells to the CD34 stem cell population would
eem to increase the level of stem cell migration and
roliferation in the marrow niche after SCT.
In a subgroup analysis, the role of higher trans-
lant Tc or NK cell dose was profound in terms of OS
nd NRM in myeloablative conditioning settings but
ot deﬁnite in an RIC setting. Further prospective
tudy may reach on a clear conclusion on this issue.
Rapid neutrophil engraftment was also found to
orrelate strongly with improved transplantation out-
omes, ie, OS and NRM. Although this improvement
as not fully mediated by decreasing the neutropenic
eriod and chance of subsequent opportunistic infec-
ions during the early period after transplantation, a
ong-term effect was maintained during ﬁrst year after
ransplantation based on a relative plateau for the
umulative incidence of NRM. One proposed mech-
nism for this was that the factor determining the
eutrophil engraftment speed also affected long-term
ransplantation outcomes. As shown in Figure 3, the
ransplant dose of NK and Tc cells was signiﬁcantly
orrelated with the immune reconstitution. Therefore,
nvolvement of NK and Tc cells in the reconstruction of
he immune network after the thymus has been damaged
y the conditioning regimen and/or GVHD implies that
higher transplant dose of Tc and NK cells could result
n faster neutrophil engraftment and faster reconstitu-
ion of the lymphoid system.
Further, the present study found that the trans-
lant dose of CD34 cells was associated with the
evelopment of chronic GVHD, but not with trans-
lantation outcomes, which was similar to the results
f previous studies [14,15]. No correlation was noted
etween the incidence of acute/chronic GVHD and
he transplant dose of NK and Tc cells, suggesting the
xistence of a threshold NK and Tc cell dose, above
hich the risk of acute/chronic GVHD is not substan-
ially increased. Thus, a higher transplant dose of NK
nd Tc cells may be beneﬁcial for (1) accelerating
eutrophil engraftment, (2) not increasing the risk of
VHD, (3) improving the immune reconstitution
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D. H. Kim et al.728ithin 1 year, and (4) decreasing NRM after alloge-
eic PBSCT.
In conclusion, the present ﬁndings suggested that
higher transplant dose of NK or Tc cells accelerates
eutrophil engraftment, improves immune reconsti-
ution, and decreases NRM, thereby improving OS
fter allogeneic PBSCT. Therefore, even though the
umber of CD34 cells infused is critical for success-
ul allografting, in a further prospective protocol, a
igher transplant dose of non-CD34 cell composites
ogether with CD34 cells needs to be considered to
chieve better transplantation outcomes after alloge-
eic PBSCT.
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